# enEvolv

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enevolv

- Industry: Biotechnology
- Headquarters: Medford, US
- Website: www.enevolv.com
- Total disclosed funding: $1.3M
- Latest round: Series A (Feb 20, 2014)
- Investors on record: 1

## About

enEvolv, Inc. is a biotechnology company developing innovative solutions in synthetic biology for various industries, including agriculture and biopharma, enhancing operational efficiency and product development.Founded in 2011 in Medford, US, enEvolv, Inc. provides biotechnology solutions in synthetic biology. The company has undergone no publicly mentioned pivots. It was acquired by Zymergen, Inc. in March 2020. Farren Isaacs is identified as the founder, and Colin South currently serves as CEO. The company has successfully raised USD 1.310 mn in its Series A funding round led by Cultivian Sandbox Ventures, with a total amount raised of USD 1.310 mn and a current valuation of USD 6.642 mn.enEvolv specializes in biotechnology solutions, focusing on synthetic biology to serve sectors such as agriculture, biopharma, and biosecurity. Their offerings encompass AI models, data generation, and lab automation technologies aimed at improving R&D capabilities and operational efficiency for clients, which include agricultural firms and biopharmaceutical companies across North America, Europe, and Asia.enEvolv generates revenue through a comprehensive business model involving B2B transactions, partnerships, and subscription services. Revenue streams are derived from subscription access to their proprietary platforms and direct sales of services, catering to the specific needs of clients across various sectors by providing tailored research and development solutions.EnEvolv's future growth strategy includes expanding its product offerings and entering new markets. The company aims to design and launch upcoming solutions in synthetic biology, specifically targeting the agricultural and biopharma sectors. Recent funding from the Series A round will be utilized to scale operations and develop new technologies. Given the acquisition by Zymergen, the company is likely to benefit from expanded resources and market reach.

## Funding rounds

- Series A, Feb 20, 2014, $1.3M — Cultivian Sandbox Ventures

## Investors

- Cultivian Sandbox Ventures (https://capitalatlas.ai/funds/cultivian-sandbox-ventures) — Series A